Skip to content

clinical research on siddha medicine Gendhaga Vallaathi in the treatment of Uthira Vaatha Suronitham(Rheumatoid Arthritis)

Clinical study on Uthira Vaatha Suronitham(Rheumatoid Arthritis)and the drug of choice is Gendhaga Vallaathi (Internal) and Vaatha samhari Thylam(External)

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2014/11/005180
Enrollment
40
Registered
2014-11-07
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- UTHIRA VAATHA SURONITHAM (Rheumatoid arthritis)

Interventions

Intervention1: Gendhaga Vallaathi (Internal) and Vaatha samhari thylam(External): 6 gms of Gendhaga Vallaathi administered orally twice a day for a period of 48 days.Vaatha samhari thylam(External)wil

Sponsors

AYOTHIDOSS PANDITHAR HOSPITAL
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1) Guidelines for classification : a. 4 of 7 criteria are required to classify a patient as having RA b. Patients with 2 or more clinical diagnosis are not excluded 3) Criteria : Morning stiffness: stiffness in and around the joints lasting 1 hr before maximal improvement. 2) Arthritis of 3 or more joint areas: Atleast 3 joints areas , have soft tissue swellings or joint effusions not just bony overgrowth.The 14 possible joints areas involved are right or left proximal interphalangeal joint,metacarpophalangealjoint,wrist,elbow,knee,ankle, metatarsophalangeal joint 3) Symmetrical arthritis 4) Arthritis of hand joints-these should be atleast 6 weeks 5) Rheumatoid factor positive 6) Rheumatoid nodules [21] 7) Anti â?? CCP positive 8) Patients who had the pain score of 0 to 6. 9) Patients willing for admission and stay in IPD or willing to attend OPD 10)Patient willing to undergo Radiological investigation and provide blood and urine for laboratory investigation. 11) Patient willing to sign the informed consent stating that he/she will consciously stick to the treatment during 48 days but can opt out of the trial of his/her own conscious discretion.

Exclusion criteria

Exclusion criteria: •Diabetes Mellitus •Hypertension •Pregnancy and lactation •Any other serious systemic illness •Drug Addicts •SLE •H/O undergone DMARDs (past 3 month) •Patients who had the pain score of 7 to 10 •Osteoarthritis •Tubercular Arthritis •Gouty Arthritis •Psoriatic Arthritis

Design outcomes

Primary

MeasureTime frame
It is mainly assessed by UNIVERSAL PAIN ASSESSMENT SCALE- Numeric Rating Scale before and after treatment. UNIVERSAL PAIN ASSESMENT SCALE: Grade 0 : No Pain Grade 1 -3 : Mild pain Grade 4-6 : Moderate pain Grade 7-10: Severe pain Timepoint: PRE STUDY SCREENING AND AFTER TREATMENT

Secondary

MeasureTime frame
It is assessed by the following parameters before and after treatment. 1.Reduction in clinical symptoms 2.Health Assessment Questionnarie [20] 3.Hb and ESR variations. 4.RA and CRP variations Timepoint: PRE STUDY SCREENING AND AFTER TREATMENT

Countries

India

Contacts

Public ContactDR H VETHA MERLIN KUMARI

NATIONAL INSTITUTE OF SIDDHA

drmohan139@gmail.com044-22411611

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026